NBGIX
Price
$59.11
Change
-$0.04 (-0.07%)
Updated
Jun 22 closing price
Net Assets
7.49B
WCMLX
Price
$15.84
Change
+$0.19 (+1.21%)
Updated
Jun 22 closing price
Net Assets
55.19M
Interact to see
Advertisement

NBGIX vs WCMLX

NBGIX vs WCMLX Comparison Chart in %
View a ticker or compare two or three
VS
NBGIX vs. WCMLX commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBGIX is a Buy and WCMLX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
NBGIX has more cash in the bank: 7.49B vs. WCMLX (55.2M). NBGIX pays higher dividends than WCMLX: NBGIX (0.32) vs WCMLX (0.00). NBGIX was incepted earlier than WCMLX: NBGIX (27 years) vs WCMLX (7 years). WCMLX (1.79) is less costly to investors than NBGIX (0.84). WCMLX is a more actively managed with annual turnover of: 89.00 vs. NBGIX (23.00). WCMLX has a lower initial minimum investment than NBGIX: WCMLX (100000) vs NBGIX (1000000). WCMLX annual gain was more profitable for investors over the last year : 29.66 vs. NBGIX (-3.11). WCMLX return over 5 years is better than : -0.32 vs. NBGIX (-20.87).
NBGIXWCMLXNBGIX / WCMLX
Total Expense Ratio0.840.9985%
Annual Report Gross Expense Ratio0.841.7947%
Fund Existence27 years7 years-
Gain YTD9.82913.73572%
Front LoadN/AN/A-
Min. Initial Investment10000001000001,000%
Min. Initial Investment IRAN/AN/A-
Net Assets7.49B55.2M13,569%
Annual Yield % from dividends0.320.00-
Returns for 1 year-3.1129.66-10%
Returns for 3 years1.6036.684%
Returns for 5 years-20.87-0.326,554%
Returns for 10 years13.37N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JHEIX15.28N/A
N/A
JHancock Equity Income A
SILVX18.93N/A
N/A
SGI US Large Cap Equity I
JLCVX71.74N/A
N/A
JHancock Fundamental Large Cap Core R5
JGISX100.14N/A
N/A
JPMorgan U.S. GARP Equity R6
EEMGX12.91N/A
N/A
MFS Emerging Markets Equity Research R4